Actuate Therapeutics(ACTU) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ACTU Actuate Therapeutics

Watchlist

7.270
+0.520+7.70%

Trading Mar 24 13:42 ET

141.99MMarket Cap-5.20P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

H.C. Wainwright Initiates Actuate Therapeutics(ACTU.US) With Buy Rating, Announces Target Price $20
Moomoo NewsMar 17 21:32 ET · Ratings
Express News | Actuate Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $20
ReutersMar 17 06:05 ET
Actuate Therapeutics | 10-K: FY2024 Annual Report
SECMar 13 16:30 ET · Announcements
Express News | Actuate Completes Enrollment In Phase 2 Trial Of Elraglusib Plus FOLFIRINOX And Losartan
BenzingaFeb 25 08:20 ET
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination With FOLFIRINOX and Losartan in Patients With Previously Untreated Metastatic Pancreatic Cancer
GlobeNewswireFeb 25 08:00 ET
Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans?
Yahoo FinanceFeb 12 05:55 ET

Comments

Jaguar8

Feb 25 21:05

NEWS

$Actuate Therapeutics (ACTU.US)$
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
Tuesday, 25th February at 8:00 am
• Initial Data from this Phase 2 Trial Demonstrates Early Evidence of Clinical Activity of Elraglusib (9-ING-41) in Combination with FOLFIRINOX and Losartan in Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
• The Final Results...

Jaguar8

Jan 7 21:13

NEWS

$Actuate Therapeutics (ACTU.US)$
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
Tuesday, 7th January at 8:00 am
CHICAGO and FORT WORTH, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen...

Jaguar8

Dec 18, 2024 06:55

🟡Watchlist WEDNESDAY December 18,2024

NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 months✅
$Wearable Devices (WLDS.US)$ PR 12/17:...

Trump announces $500 billion "Stargate" project! Powerful catalyst for AI?

Jaguar8

Dec 17, 2024 21:06

NEWS

$Actuate Therapeutics (ACTU.US)$
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
Tuesday, 17th December at 8:00 am
• Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall Survival
• Doubling of 1 Year Survival Rate and 37% Reduction in Risk of Death
• Two Month (29%) Increase in Median Overall Survival
• Multiple Patients with Complete Responses (CRs) and/or Partial Re...